Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
نویسندگان
چکیده
OBJECTIVES To evaluate the effectiveness of tumour necrosis factor (TNF) blockers in juvenile psoriatic arthritis (JPsA). METHODS The study was a prospective ongoing multicentre, observational study of all Dutch juvenile idiopathic arthritis (JIA) patients using biologicals. The response of arthritis was assessed by American College of Rheumatology (ACR) paediatric response and Wallace inactive disease criteria. The response of psoriatic skin lesions was scored by a 5-point scale. RESULTS Eighteen JPsA patients (72% female, median age onset 11.1 (range 3.3-14.6) years, 50% psoriatic skin lesions, 39% nail pitting, 22% dactylitis) were studied. The median follow-up time since starting anti-TNFα was 26 (range 3-62) months. Seventeen patients started on etanercept and one started on adalimumab. After 3 months of treatment 83% of the patients achieved ACR30 response, increasing to 100% after 15 months. Inactive disease reached in 67% after 39 months. There was no discontinuation because of inefficacy. Six patients discontinued treatment after a good clinical response. However, five patients flared and restarted treatment, all with a good response. During treatment four patients (two JPsA and two JIA patients with other subtypes) developed de novo psoriasis. In four of the nine patients the pre-existing psoriatic skin lesions improved. CONCLUSION Anti-TNFα therapy in JPsA seems effective in treating arthritis. However, in most patients the arthritis flared up after treatment discontinuation, emphasising the need to investigate optimal therapy duration. The psoriatic skin lesions did not respond well and four patients developed de novo psoriasis.
منابع مشابه
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
High levels of proinflammatory cytokines, including tumour necrosis factor (TNF), have been detected in psoriatic skin lesions and joints of patients with the inflammatory disease. Early results of treatment of psoriatic arthritis and psoriasis with TNF neutralising agents are encouraging, but whether these agents will be able to improve long term outcomes, such as disability, is not yet known.
متن کاملTreatment of psoriasis with etanercept in immunocompromised patients: Two case reports
Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and...
متن کاملAnti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
The efficacy of B-cell depletion therapy in rheumatoid arthritis (RA) has led to a renewed interest in B cells and their products and the role they play in the pathogenesis of the disease. Agents blocking tumour necrosis factor (TNF) are also very effective in the treatment of RA. It has long been known that the use of anti-TNF therapy can be associated with development of anti-nuclear and anti...
متن کاملPReS-FINAL-2026: Glucose and lipid metabolism in children with juvenile idiopathic arthritis treated with anti-TNF-alpha
Introduction Inflammation and inflammatory mediators may affect glucose and lipid metabolism through a number of pathways. However, effects and mechanisms seem to vary dramatically in different individuals and settings. In obese adults with metabolic syndrome and impaired glucose-tolerance, inflammatory mediators from fat tissue including tumour necrosis factor-alpha (TNF-a) further reduce gluc...
متن کاملProspects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
Tumour necrosis factor (TNF) blockade, achieved by the soluble receptors and antibodies, has been a major success in the treatment of rheumatoid arthritis (RA). The success of this treatment has also established biological agents as a new weapon in the armoury of therapeutic approaches to the treatment of autoimmune diseases. Established data and emerging evidence suggest that anti-TNF biologic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of the rheumatic diseases
دوره 70 2 شماره
صفحات -
تاریخ انتشار 2011